Professional
Added to YB: 2025-02-18
Pitch date: 2025-02-17
HROW [bullish]
Harrow, Inc.
+54.04%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.6B
Pitch Price
$30.55
Price Target
122.00 (+159%)
Dividend
N/A
EV/EBITDA
38.20
P/E
-324.83
EV/Sales
7.29
Sector
Pharmaceuticals
Category
growth
Generation PMCA Portfolio Holding: Harrow, Inc.
HROW: Ophthalmic pharma co. w/ 17 eye therapies. New drugs IHEEZO (ocular anesthetic gel, 82% reorder) & VEVYE (water-free cyclosporine, 92% refill) to boost sales. $1.1B mkt cap. Mgmt guides $1B rev by 2027 (~$300M earnings). FMV est. 4x current price. Risks: new profitability, competition, sales team execution.
Read full article (1 min)